论文部分内容阅读
肿瘤标志物的研究与应用在肿瘤学中已成为一个引人注目的新领域。研究表明,血清肿瘤标志物的最佳联合检测对于胰腺癌诊断、疗效观察、监测复发或转移、指导治疗及判断预后有重要的意义。国内外大量文献显示联合检测是目前较为理想的肿瘤标志物;肿瘤标志物有望在胰腺癌临床中成为早期诊断、预后判断及调整治疗的工具,CA19-9、CA24-2、K-ras、p53和p16肿瘤标志物具有重要的应用价值。现结合国内外近年来的文献,就肿瘤标志物在胰腺癌诊治中的研究进展作一综述。
The research and application of tumor markers have become a new field attracting attention in oncology. Studies have shown that the optimal combination of serum tumor markers for pancreatic cancer diagnosis, observation of efficacy, monitoring recurrence or metastasis, guiding treatment and prognosis of great significance. A large number of literatures at home and abroad show that the combined detection is the ideal tumor marker at present. Tumor markers are expected to become the tools of early diagnosis, prognosis judgment and adjustment treatment in the clinical diagnosis of pancreatic cancer. CA19-9, CA24-2, K-ras, p53 And p16 tumor markers have important application value. Now combined with the literature at home and abroad in recent years, the progress of tumor markers in the diagnosis and treatment of pancreatic cancer are reviewed.